CDC: Public Domain
CDC: Public Domain

Using machine learning to find new antibiotics

Embargoed until: Publicly released:

Despite growing concerns about antibiotic resistance, the discovery of new antibiotic drugs has slowed as new molecules become increasingly difficult to identify. Now, US researchers have road tested a new method to uncover new antibiotics quickly and efficiently through machine learning. By training computer algorithms to identify potential candidates, the authors say we might be able to “usher in the Second Age of Antibiotics.”

Journal/conference: Cell

Link to research (DOI): 10.1016/j.cell.2020.01.021

Organisation/s: Massachusetts Institute of Technology, USA

Funder: This work was supported by the Abdul Latif Jameel Clinic for Machine Learning in Health; the Defence Threat Reduction Agency; the Broad Institute of MIT and Harvard; the DARPA Make-It program; the Defence Threat Reduction Agency; the Canadian Institutes of Health Research; the Canadian Foundation for Innovation; the Canada Research Chairs Program; the Banting Fellowships Program; the Human Frontier Science Program; the Broad Institute Tuberculosis Donor Group and the Pershing Square Foundation; the Swiss National Science Foundation; NIH Early Investigator Award; National Science Foundation; and by a generous gift from Anita and Josh Bekenstein

Media Release

From: Cell Press

Peer-reviewed            Experimental Study            Animals/Mice

Researchers identify novel antibiotics using machine learning

Despite growing concerns about antibiotic resistance, the discovery of new antibiotic drugs has slowed as new molecules become increasingly difficult to identify. But in a paper publishing February 20 in the journal Cell, researchers demonstrate a method to uncover new antibiotics quickly and efficiently through machine learning.

James Collins, a synthetic biologist at MIT, and his team trained a deep neural network to identify possible antibiotic molecules using compounds known to suppress E. coli growth; the network then used these data to examine other molecules in existing chemical libraries and predict their likelihood to suppress growth of bacteria. The researchers found that nearly 50% of those compounds they prioritized to test showed some effectiveness in vitro in limiting E. coli proliferation. One compound in particular, halicin, is structurally divergent from conventional antibiotic molecules and uses a mechanism that’s uncommon in clinical antibiotics to fight a wide range of human pathogens in mice, including Clostridioides difficile and Acinetobacter baumannii.

While these vast libraries of molecules have been available as potential sources of new antibiotics, researchers haven’t had an efficient way before now to curate them to identify promising candidates for experimental testing. But if widely adopted, deep neural networks could save both time and resources in the search for new, unique antibiotics—something, the authors say, that is necessary in part because of a lack of economic incentives for their discovery. They write, “deep learning approaches could enable us to outpace the emergence of multidrug-resistant pathogens and usher in the Second Age of Antibiotics.”

Attachments:

Note: Not all attachments are visible to the general public

  • Cell Press
    Web page
    URL will go live after the embargo ends

News for:

International

Media contact details for this story are only visible to registered journalists.